ReviewCurrent allergy and asthma reports2015
Anaphylaxis to insect venom allergens: role of molecular diagnostics.
Review in Current allergy and asthma reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 92 citations in OpenAlex.
- Multi-Omics Analyses Elucidate the Venom Components of the WaspEcology and evolution · 2026Article
- Immunosenescence and Allergy: Molecular and Cellular Links Between Inflammaging, Neuro-Immune Aging, and Response to Biologic Therapies.International journal of molecular sciences · 2026Review
- Article
- Habitat Suitability Modelling for the Red Dwarf Honeybee (Apis florea (Linnaeus)) and Its Distribution Prediction Using Machine Learning and Cloud Computing.Neotropical entomology · 2024Article
- Bee Venom Toxic Effect on MDA-MB-231 Breast Cancer Cells andAnti-cancer agents in medicinal chemistry · 2024Article
- Article
- Diagnosis ofBiomedicines · 2022Review
- Profiling hymenopteran venom toxins: Protein families, structural landscape, biological activities, and pharmacological benefits.Toxicon: X · 2022Article
- Component-Resolved Evaluation of the Risk and Success of Immunotherapy in Bee Venom Allergic Patients.Journal of clinical medicine · 2022Article
- Review
- New Biomarkers ofInternational journal of environmental research and public health · 2021Article
- Immunological Responses to Envenomation.Frontiers in immunology · 2021Review
- CpG Adjuvant in Allergen-Specific Immunotherapy: Finding the Sweet Spot for the Induction of Immune Tolerance.Frontiers in immunology · 2021Review
- Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis.Allergologie select · 2021Article
- Expression of eosinophils, RANTES and IL-25 in the first phase of Hymenoptera venom immunotherapy.Postepy dermatologii i alergologii · 2020Article
- Antigen 5 Allergens of Hymenoptera Venoms and Their Role in Diagnosis and Therapy of Venom Allergy.Current allergy and asthma reports · 2020Review
- Article
- Improved production of the recombinant phospholipase A1 from3 Biotech · 2020Article
- Review
- Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaphylaxis due to Hymenoptera stings is one of the most severe consequences of IgE-mediated hypersensitivity reactions. Although allergic reactions to Hymenoptera stings are often considered as a general model for the underlying principles of allergic disease, diagnostic tests are still hampered by a lack of specificity and venom immunotherapy by severe side effects and incomplete protection. In recent years, the knowledge about the molecular composition of Hymenoptera venoms has significantly increased and more and more recombinant venom allergens with advanced characteristics have become available for diagnostic measurement of specific IgE in venom-allergic patients. These recombinant venom allergens offer several promising possibilities for an improved diagnostic algorithm. Reviewed here are the current status, recent developments, and future perspectives of molecular diagnostics of venom allergy. Already to date, it is foreseeable that component-resolution already has now or will in the future have the potential to discriminate between clinically significant and irrelevant sensitization, to increase the specificity and sensitivity of diagnostics, to monitor immunotherapeutic intervention, and to contribute to the understanding of the immunological mechanisms elicited by insect venoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.